US-based developer of haemodynamic transesophageal echocardiography (hTEE) technology ImaCor has launched its all-in-one platform for advanced haemodynamic management, including hTEE, hTTE and the Zura ultrasound systems.
The company said that hTEE is enabled by the ClariTEE probe, which can be left indwelling for 72 hours, while hTTE is a transthoracic probe for complementary haemodynamic management.
The Zura ultrasound systems, including the Zura EVO-1, which is the latest model in the Zura EVO family, provide new advanced processing for high-definition imaging.
Thomas Jefferson University Hospital director of the Surgical Critical Care Unit Nicholas Cavarocchi said: "I am impressed with the significant image quality improvements on ImaCor’s all-in-one haemodynamic management platform; it provides the whole picture in critical care."
The company’s haemodynamic management platform also includes haemodynamic trending, displaying cardiac filling and function data over time in a dashboard format.
Additional features include sizeable image quality improvements with a 7mHz resolution at 18cm depth.
ImaCor president and CEO Peter Pellerito said: "Strategically, our all-in-one haemodynamic management platform fulfils our vision of providing the most advanced technology in critical care.
"The new system delivers a higher level of capabilities to our customers, avoiding dramatic cost, while saving time, money, and ultimately, lives."
Meanwhile, the US Food and Drug Administration (FDA) has granted the company’s transthoracic echocardiography (TTE) probe 510(k) clearance, making its platform the first-of-its-kind for haemodynamic management.
Image: ImaCor all-in-one haemodynamic management platform with hTEE technology enabled by a ClariTEE probe and 510(K) cleared hTTE probe. Photo: courtesy of Business Wire.